JAK2 and myeloproliferative neoplasm: Our work demonstrating that AZD1208 synergizes with ruxolitinib to inhibit primary MPN cell colony formation provides additional and significant pre-clinical data that PIM inhibition may increase the therapeutic efficacy of JAK2 inhibitors (Fig. 4).